Acquired resistance through secondary mutations and bypass evolution remains a major hurdle in targeted lung cancer therapy. Overcoming tumor escape to restore drug sensitivity has become a critical demand in global precision medicine. This technology focuses on a highly selective inhibitor that targets bypass signals generated by specific genetic mutations. When combined with existing targeted therapies, it effectively blocks escape routes and extends patient survival. By addressing key unmet needs with mechanistic precision, this approach delivers exceptional clinical value in the lung cancer landscape.